共 69 条
Toxoplasmosis in Pediatric Hematopoietic Stem Cell Transplantation Patients
被引:16
作者:
Schwenk, Hayden T.
[1
,2
]
Khan, Aslam
[1
,2
]
Kohlman, Krystal
[1
]
Bertaina, Alice
[1
,3
]
Cho, Stephanie
[4
]
Montoya, Jose G.
[5
]
Contopoulos-Ioannidis, Despina G.
[1
,2
,5
]
机构:
[1] Lucile Packard Childrens Hosp Stanford, Palo Alto, CA USA
[2] Stanford Univ, Dept Pediat, Div Infect Dis, Sch Med, 300 Pasteur Dr,Room G312, Stanford, CA 94305 USA
[3] Stanford Univ, Dept Pediat, Div Stem Cell Transplantat & Regenerat Med, Sch Med, Stanford, CA 94305 USA
[4] Stanford Univ, Community Hlth & Prevent Res Masters Grad Program, Sch Med, Stanford, CA 94305 USA
[5] Palo Alto Med Fdn, Dr Jack S Remington Lab Specialty Diagnost, Palo Alto, CA USA
来源:
TRANSPLANTATION AND CELLULAR THERAPY
|
2021年
/
27卷
/
04期
关键词:
Toxoplasma gondii;
Toxoplasmosis;
Hematopoietic stem cell transplantation;
HSCT;
Transplant;
Pediatric;
BONE-MARROW-TRANSPLANTATION;
CEREBRAL TOXOPLASMOSIS;
GONDII INFECTION;
ATOVAQUONE PROPHYLAXIS;
UNITED-STATES;
RECIPIENTS;
BLOOD;
ENCEPHALITIS;
DIAGNOSIS;
COMPLICATIONS;
D O I:
10.1016/j.jtct.2020.11.003
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Infection due to the protozoa Toxoplasma gondii can be life-threatening in hematopoietic stem cell transplantation (HSCT) recipients. Most cases of toxoplasmosis in HSCT recipients result from reactivation of latent infection in individuals who were Toxoplasma-seropositive before transplantation and did not receive appropriate prophylaxis. Pretransplantation screening with Toxoplasma IgG and IgM antibodies is suggested for all allogeneic HSCT recipients and their donors and all autologous HSCT recipients. Prevention of toxoplasmosis in T. gondii-seropositive HSCT recipients requires primary prophylaxis, preemptive screening, or both. Trimethoprim-sulfamethoxazole (TMP-SMX) is the preferred agent for Toxoplasma prophylaxis and should be continued for 6 months or until the patient is no longer receiving immunosuppression, whichever is longer, assuming that immune reconstitution has occurred. Preemptive weekly screening with whole blood Toxoplasma PCR should be considered for seropositive HSCT recipients if prophylaxis cannot be given or if prophylaxis other than TMP-SMX is used. The signs, symptoms, and radiographic findings of toxoplasmosis in HSCT recipients can be nonspecific, and the diagnosis requires a high degree of suspicion. Common presentations include fever, encephalopathy with mental status changes or seizures, and pneumonia. A Toxoplasma PCR analysis from whole blood (and other body fluids/tissues according to clinical symptoms) should be obtained in patients in whom there is a concern for toxoplasmosis. Treatment with oral pyrimethamine, sulfadiazine, and leucovorin for at least 6 weeks is the first-line therapy and should be followed by secondary prophylaxis. In this article, we review the published literature regarding the epidemiology, clinical presentation, treatment, and prevention of toxoplasmosis in HSCT recipients. (C) 2020 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:292 / 300
页数:9
相关论文